Breonics Overview
- Year Founded
-
1996
- Status
-
Private
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$2M
- Investors
-
1
Breonics General Information
Description
Developer of exsanguinous metabolic support technology designed to broaden the criteria for kidney donors. The company's technology maintains continued oxidative metabolism and function of organs and tissues while isolated from the rest of the human body to expand the window of time for organ recovery, enabling healthcare practitioners to overcome the technical barriers related to organ transplants and donations.
Contact Information
Website
www.breonics.comCorporate Office
- 44 Dalliba Avenue
- Suite 100
- Watervliet, NY 12189
- United States
Corporate Office
- 44 Dalliba Avenue
- Suite 100
- Watervliet, NY 12189
- United States
Breonics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC | 30-Dec-2020 | $2M | Completed | Pre-Clinical Trials | ||
| 7. Secondary Transaction - Private | Completed | Pre-Clinical Trials | ||||
| 6. Grant | 01-Jan-2014 | Completed | Pre-Clinical Trials | |||
| 5. Grant | 18-Sep-2012 | Completed | Pre-Clinical Trials | |||
| 4. Grant | 01-Sep-2010 | Completed | Pre-Clinical Trials | |||
| 3. Grant | 01-Jan-2009 | Completed | Pre-Clinical Trials | |||
| 2. Later Stage VC | $4.2M | $4.2M | Completed | Startup | ||
| 1. Grant | 01-Jan-2001 | $100K | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Breonics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Breonics Patents
Breonics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20160160176-A1 | Reducing the immunogenicity of allografts | Active | 09-Oct-2014 | ||
| US-9994811-B2 | Reducing the immunogenicity of allografts | Inactive | 09-Oct-2014 | ||
| US-20140220548-A1 | Methods and compositions to modify the immunogenicity of a vascularized organ or tissue | Active | 05-Nov-2012 | ||
| US-9232784-B2 | Methods and compositions to modify the immunogenicity of a vascularized organ or tissue | Inactive | 05-Nov-2012 | ||
| CA-2846590-A1 | Organ chamber for ex vivo warm perfusion | Inactive | 25-Aug-2011 | A01N1/143 |
Breonics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Fischli Venture | Venture Capital | Minority |
Breonics FAQs
-
When was Breonics founded?
Breonics was founded in 1996.
-
Where is Breonics headquartered?
Breonics is headquartered in Watervliet, NY.
-
What industry is Breonics in?
Breonics’s primary industry is Other Healthcare Technology Systems.
-
Is Breonics a private or public company?
Breonics is a Private company.
-
What is Breonics’s current revenue?
The current revenue for Breonics is .
-
How much funding has Breonics raised over time?
Breonics has raised $6.2M.
-
Who are Breonics’s investors?
Fischli Venture has invested in Breonics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
